

Margreet G Franken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9195777/publications.pdf>

Version: 2024-02-01

33
papers

732
citations

567281

15
h-index

552781

26
g-index

33
all docs

33
docs citations

33
times ranked

1196
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1312-1319.	1.6	107
2	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165.	2.8	77
3	SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 349-357.	0.5	62
4	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. <i>European Journal of Cancer</i> , 2019, 123, 58-71.	2.8	45
5	A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. <i>Pharmacoeconomics</i> , 2015, 33, 551-560.	3.3	30
6	A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. <i>Health Policy</i> , 2015, 119, 195-202.	3.0	29
7	Health system goals: A discrete choice experiment to obtain societal valuations. <i>Health Policy</i> , 2013, 112, 28-34.	3.0	27
8	Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. <i>Value in Health</i> , 2017, 20, 627-636.	0.3	27
9	Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. <i>Pharmacoeconomics</i> , 2013, 31, 781-797.	3.3	26
10	Potential cost savings owing to the route of administration of oncology drugs. <i>Anti-Cancer Drugs</i> , 2018, 29, 791-801.	1.4	23
11	EUROPEAN DRUG REIMBURSEMENT SYSTEMS' LEGITIMACY: FIVE-COUNTRY COMPARISON AND POLICY TOOL. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 358-366.	0.5	22
12	Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , 2019, 11, 1007.	3.7	22
13	The Unit Costs of Inpatient Hospital Days, Outpatient Visits, and Daycare Treatments in the Fields of Oncology and Hematology. <i>Value in Health</i> , 2010, 13, 712-719.	0.3	21
14	Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. <i>European Journal of Cancer</i> , 2013, 49, 8-16.	2.8	17
15	Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 825-831.	1.0	17
16	Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. <i>Haematologica</i> , 2019, 104, 1026-1035.	3.5	17
17	Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously?. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2014, 108, 383-389.	0.9	16
18	Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study. <i>European Journal of Cancer</i> , 2021, 154, 111-119.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	3.7	15
20	Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries. <i>Value in Health</i> , 2016, 19, 951-956.	0.3	14
21	Policyholder, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policyholder Uncertainty Regarding Value for Money of Bortezomib?. <i>Value in Health</i> , 2014, 17, 245-253.	0.3	11
22	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	1.4	11
23	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	1.4	11
24	Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. <i>Breast</i> , 2020, 52, 71-77.	2.2	11
25	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	3.7	11
26	Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. <i>ESMO Open</i> , 2021, 6, 100320.	4.5	10
27	The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. <i>BMC Family Practice</i> , 2018, 19, 31.	2.9	9
28	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018, 28, 326-332.	1.2	8
29	Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e213497.	5.9	7
30	Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. <i>Health Policy</i> , 2013, 112, 285-296.	3.0	6
31	Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. <i>Health Policy</i> , 2015, 119, 186-194.	3.0	6
32	Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. <i>Melanoma Research</i> , 2021, 31, 249-257.	1.2	1
33	Reply to X. Armoiry et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2976-2977.	1.6	0